首页> Journal of the International AIDS Society> Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg.

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg.

导出 OA

翻译打印收藏纠错

第一作者： Eva,Natukunda

第一单位： Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda.

作者： Eva,Natukunda ^[1] ; Aditya H,Gaur ^[2] ; Pope,Kosalaraksa ^[3] ; Elizabeth,Hellström ^[4] ; Renate,Strehlau ^[5] ; Afaaf,Liberty ^[6] ; Stephanie,Cox ^[7] ; Rory,Leisegang ^[7] ; Ramesh,Palaparthy ^[7] ; Susanne,Crowe ^[7] ; Vinicius,Vieira ^[7] ; Kathryn,Kersey ^[7] ; Natella,Rakhmanina ^[8]

作者单位： Department of Paediatrics, Joint Clinical Research Centre, Kampala, Uganda. ^[1] Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. ^[2] Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. ^[3] Be Part Yoluntu Centre, Paarl, South Africa. ^[4] Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa. ^[5] Chris Hani Baragwanath Hospital, Johannesburg, South Africa. ^[6] Gilead Sciences, Inc., Foster City, California, USA. ^[7] Children's National Hospital, Washington, DC, USA.;The George Washington University, Washington, DC, USA.;Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA. ^[8]

关键词 E/C/F/TAF HIV‐1 antiretroviral therapy children elvitegravir tenofovir alafenamide